3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
4
Recruiting
3
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
50
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
11
Neoplasm Metastasis
10
Carcinoma, Renal Cell
7
Skin Neoplasms
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Glioblastoma
4
Diabetes Mellitus, Insulin-Dependent, 12
4
Carcinoma, Hepatocellular
4
Brain Neoplasms
4
Advanced Cancer
4
Uveal Melanoma
3
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Breast Neoplasms
3
Waldenstrom Macroglobulinemia
2
Sarcoma
2
Myeloproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Interventions
Sorafenib
12
Radiosurgery
5
Gemcitabine
5
Capecitabine
5
Bevacizumab
5
Radiotherapy
4
Fluorouracil
4
Doxorubicin
4
Sunitinib
3
Oxaliplatin
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
seocalcitol
2
regorafenib
2
phosphomannopentaose sulfate
2
atezolizumab
2
Thiotepa
2
Radiofrequency Ablation
2
Melphalan
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Dexamethasone
2
Cisplatin
2
Chemoembolization, Therapeutic
2
Carboplatin
2
Busulfan
2
Brachytherapy
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Liver Neoplasms
×
Ipilimumab
×
Clear all
NCT04311710
2023-02-24
CheckMate 76U
Bristol-Myers Squibb
Phase 1
Terminated
21 enrolled